Durvalumab and Topotecan for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effects of durvalumab and topotecan in treating patients with
extensive stage small cell lung cancer that has come back (relapsed) or has not responded to
previous treatment with chemotherapy and immunotherapy (refractory). Monoclonal antibodies,
such as durvalumab, may interfere with the ability of tumor cells to grow and spread.
Topotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth Giving durvalumab and topotecan may help kill more tumor cells and help patients live
longer.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antibodies, Monoclonal Durvalumab Immunoglobulin G Immunoglobulins Topotecan